Epigral Ltd

Epigral Ltd’s share price declined to a fresh 52-week low of Rs.806.2 on 30 March 2026, marking a significant drop amid broader market weakness and sectoral pressures. The stock’s recent performance reflects ongoing challenges in both near-term results and longer-term growth metrics within the specialty chemicals sector.

Epigral Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 26 December 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 29 March 2026, providing investors with an up-to-date view of the company’s performance and outlook.

Despite a broader market rally, Epigral Ltd has plunged to a fresh 52-week low of Rs 822 on 23 Mar 2026, marking a steep 57.05% decline over the past year and underscoring persistent headwinds unique to the stock.

Epigral Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 26 December 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 18 March 2026, providing investors with an up-to-date perspective on the company’s performance and outlook.

Epigral Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 26 Dec 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 07 March 2026, providing investors with an up-to-date view of the company’s performance and outlook.

Epigral Ltd, a specialty chemicals company, opened the trading session with a pronounced gap down, reflecting heightened market concerns following a series of negative performance indicators and a downgrade in its mojo grade. The stock’s opening price plunged by 7.93%, marking a fresh 52-week low and continuing a downward trend that has persisted over the past week.

Epigral Ltd, a key player in the Specialty Chemicals sector, has touched a new 52-week low of Rs.822.05 today, marking a significant decline amid a sustained downward trend. The stock’s performance continues to lag behind its sector and broader market indices, reflecting ongoing pressures on its financial metrics and market valuation.

Epigral Ltd, a player in the Specialty Chemicals sector, recorded a fresh 52-week low of Rs.901.6 today, marking a significant milestone in its ongoing price decline. The stock has underperformed its sector and broader market indices, reflecting a challenging period for the company’s equity performance.

Epigral Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 26 December 2025. However, the analysis and financial metrics presented here reflect the stock's current position as of 24 February 2026, providing investors with an up-to-date view of the company’s performance and outlook.

Epigral Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 26 December 2025. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 12 February 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance.

Epigral Ltd recorded a robust intraday performance on 3 Feb 2026, surging to a day’s high of Rs 1001.65, marking a 7.98% increase from the previous close. The stock outperformed its sector and the broader market, reflecting notable trading momentum within the Specialty Chemicals industry.

Epigral Ltd, a player in the Specialty Chemicals sector, recorded a fresh 52-week low of Rs.933.45 today, marking a significant decline amid a sustained downward trend. The stock has underperformed its sector and broader market indices, reflecting ongoing pressures on its financial performance and valuation metrics.

Epigral Ltd’s shares declined sharply today, touching an intraday low of Rs 965, marking a new 52-week low as the stock underperformed both its sector and the broader market amid widespread selling pressure.

Epigral Ltd, a key player in the Specialty Chemicals sector, has touched a new 52-week low, closing just 0.02% above its lowest price of Rs 997.7. This marks a significant point in the stock’s recent trajectory, reflecting ongoing challenges in both its near-term and long-term performance metrics.

Epigral Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 26 December 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 01 February 2026, providing investors with the latest insights into the company’s performance and outlook.